EUVIMEDEUVIMED entdecken
Crossref

Effects of elexacaftor/tezacaftor/ivacaftor therapy in children with cystic fibrosis – a comprehensive assessment using lung clearance index, spirometry, and functional and structural lung MRI

Carmen Streibel, Corin C Willers, Orso Pusterla, Grzegorz Bauman, Enno Stranzinger, Ben Brabandt, Oliver Bieri, Marion Curdy, Marina Bullo, Bettina Sarah Frauchiger, Insa Korten, Linn Krüger und 4 weitere

Journal of Cystic Fibrosis · 2023

DOI: 10.1016/j.jcf.2022.12.012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2023. Verfasst von Carmen Streibel und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Paediatric Respiratory Medicine and Allergology, Department of Paediatrics, Inselspital, Bern University Hospital, University of Bern, Sw…. Hauptthemen laut MEDLINE: Cystic Fibrosis Transmembrane Conductance Regulator, Cystic Fibrosis. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Roche, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Cystic Fibrosis Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: With improvement in supportive therapies and the introduction of cystic fibrosis transmembrane conductance regulator (CFTR)-modulator treatment in patients with cystic fibrosis (CF), milder disease courses are expected. Therefore, sensitive parameters are needed to monitor disease course and effects of CFTR-modulators. Functional lung MRI using matrix-pencil decomposition (MP-MRI) is a promising tool for assessing ventilation and perfusion quantitatively. This study aimed to assess the treatment effect of elexacaftor/tezacaftor/ivacaftor combination regimen (ELX/TEZ/IVA) on measures of structural and functional lung abnormalities. METHODS: 24 children with CF underwent lung function tests (multiple breath washout, spirometry), functional and structural MRI twice (one year apart) before and once after at least two weeks (mean 4.7 ± 2.6 months) on ELX/TEZ/IVA. Main outcomes were changes (Δ) upon ELX/TEZ/IVA in lung function, defect percentage of ventilation (VDP) and perfusion (QDP), defect distribution index of ventilation and perfusion (DDIV, DDIQ), and Eichinger score. Statistical analyses were performed using paired t-tests and multilevel regression models with bootstrapping. RESULTS: We observed a significant improvement in lung function, structural and functional MRI parameters upon ELX/TEZ/IVA treatment (mean; 95%-CI): ΔLCI2.5 (TO) -0.84 (-1.62 to -0.06); ΔFEV1 (z-score) 1.05 (0.56 to 1.55); ΔVDP (% of impairment) -6.00 (-8.44 to -3.55); ΔQDP (% of impairment) -3.90 (-5.90 to -1.90); ΔDDIV -1.38 (-2.22 to -0.53); ΔDDIQ -0.31 (-0.73 to 0.12); ΔEichinger score -3.89 (-5.05 to -2.72). CONCLUSIONS: Besides lung function tests, functional and structural MRI is a suitable tool to monitor treatment response of ELX/TEZ/IVA therapy, and seems promising as outcome marker in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic Fibrosis Transmembrane Conductance RegulatorCystic FibrosisHumansChildRespiratory Function TestsSpirometryMagnetic Resonance ImagingLungAminophenolsBenzodioxolesMutationChloride Channel AgonistsPyrazolesPyridinesPyrrolidinesQuinolonesIndoles

Stichwörter der Autor:innen

CFTR modulator therapyChildrenCystic fibrosisElexacaftor/tezacaftor/ivacaftor therapyFunctional lung MRILung clearance indexLung diseaseLung functionMultiple breath washout

Substanzen

Cystic Fibrosis Transmembrane Conductance RegulatorAminophenolsBenzodioxolesChloride Channel AgonistselexacaftorPyrazolesPyridinesPyrrolidinesivacaftorQuinolones

Autor:innen und Institutionen

  • Division of Paediatric Respiratory Medicine and Allergology, Department of Paediatrics, Inselspital, Bern University Hospital, University of Bern, Switzerland.
  • Division of Paediatric Respiratory Medicine and Allergology, Department of Paediatrics, Inselspital, Bern University Hospital, University of Bern, Switzerland; Departement of Paediatrics, Kantonsspital Aarau, Aarau, Swi…
  • Division of Paediatric Respiratory Medicine and Allergology, Department of Paediatrics, Inselspital, Bern University Hospital, University of Bern, Switzerland; Department of Radiology, Division of Radiological Physics,…
  • Department of Radiology, Division of Radiological Physics, University of Basel Hospital, Basel, Switzerland; Department of Biomedical Engineering, University of Basel, Allschwil, Switzerland.
  • Department of Interventional and Pediatric Radiology, Inselspital, Bern University Hospital, University of Bern, Switzerland.
  • Division of Respiratory Medicine, Department of Paediatrics, The Hospital for Sick Children and University of Toronto, Toronto, Canada.

Förderung

  • Roche
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
  • Cystic Fibrosis Foundation

Zitieren

APA

Streibel, C., Willers, C. C., Pusterla, O., Bauman, G., Stranzinger, E., Brabandt, B., Bieri, O., Curdy, M., Bullo, M., Frauchiger, B. S., Korten, I., Krüger, L., Casaulta, C., Ratjen, F., Latzin, P., & Kieninger, E. (2023). Effects of elexacaftor/tezacaftor/ivacaftor therapy in children with cystic fibrosis – a comprehensive assessment using lung clearance index, spirometry, and functional and structural lung MRI. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2022.12.012

Vancouver

Streibel C, Willers CC, Pusterla O, Bauman G, Stranzinger E, Brabandt B, et al. Effects of elexacaftor/tezacaftor/ivacaftor therapy in children with cystic fibrosis – a comprehensive assessment using lung clearance index, spirometry, and functional and structural lung MRI. Journal of Cystic Fibrosis. 2023. doi:10.1016/j.jcf.2022.12.012

BibTeX
@article{Streibel2023,
  author = {Streibel, Carmen and Willers, Corin C and Pusterla, Orso and Bauman, Grzegorz and Stranzinger, Enno and Brabandt, Ben and Bieri, Oliver and Curdy, Marion and Bullo, Marina and Frauchiger, Bettina Sarah and Korten, Insa and Krüger, Linn and Casaulta, Carmen and Ratjen, Felix and Latzin, Philipp and Kieninger, Elisabeth},
  title = {Effects of elexacaftor/tezacaftor/ivacaftor therapy in children with cystic fibrosis – a comprehensive assessment using lung clearance index, spirometry, and functional and structural lung MRI},
  journal = {Journal of Cystic Fibrosis},
  year = {2023},
  doi = {10.1016/j.jcf.2022.12.012}
}
Kostenlos starten →